A vitronectin-derived peptide reverses ovariectomy-induced bone loss via regulation of osteoblast and osteoclast differentiation

Cell Death and Differentiation

Volumn 25, Issue 2, 2018, Pages 268-281

  Min, Seung Ki ^a   Kang, Hyun Ki ^b   Jung, Sung Youn ^b   Jang, Da Hyun ^b   Min, Byung Moo ^b  

^a National Cancer Center   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLVALYLTYROSYLPHENYLALANYLPHENYLALANYLLYSYLGLYCYLLYSYLGLUTAMINYLTYROSYLTRYPTOPHYLGLUTAMIC ACID; BETA1 INTEGRIN; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE 2; PEPTIDE; PROTEIN C FOS; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; VITRONECTIN; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE REGENERATION; CELL DIFFERENTIATION; CELL SURVIVAL; CHILD; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; INFANT; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; SURVIVAL RATE; ANIMAL; C57BL MOUSE; CELL LINE; CHEMISTRY; CYTOLOGY; DRUG THERAPY; METABOLISM;

ANIMALS; BONE REGENERATION; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE; HUMANS; MALE; MICE; MICE, INBRED C57BL; OSTEOBLASTS; OVARIECTOMY; PEPTIDES; VITRONECTIN;

EID: 85048368835     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2017.153     Document Type: Article

References (58)

1. Schieker M, Mutschler W. Bridging posttraumatic bony defects. Established and new methods. Unfallchirurg 2006; 109: 715-732.
2. Yaszemski MJ, Payne RG, Hayes WC, Langer R, Mikos AG. Evolution of bone transplantation: Molecular, cellular and tissue strategies to engineer human bone. Biomaterials 1996; 17: 175-185.
3. Wiesmann HP, Joos U, Meyer U. Biological and biophysical principles in extracorporal bone tissue engineering. Part II. Int J Oral Maxillofac Surg 2004; 33: 523-530.
4. Tanaka S, Nakamura K, Takahasi N, Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 2005; 208: 30-49.
5. Broadhead ML, Clark JC, Dass CR, Choong PF, Myers DE. Therapeutic targeting of osteoclast function and pathways. Expert Opin Ther Targets 2011; 15: 169-181.
6. Kim SH, Moon SH. Osteoclast differentiation inhibitors: A patent review (2008 - 2012). Expert Opin Ther Pat 2013; 23: 1591-1610.
7. Looker AC, Borrud LG, Dawson-Hughes B, Shepherd JA, Wright NC. Osteoporosis or low bone mass at the femur neck or lumbar spine in older adults: United States, 2005-2008. NCHS Data Brief 2012; 93: 1-8.
8. Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 2014; 29: 2520-2526.
9. Park SB, Park SH, Kim NH, Chung CK. BMP-2 induced early bone formation in spine fusion using rat ovariectomy osteoporosis model. Spine J 2013; 13: 1273-1280.
10. Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. Chem Biol Drug Des 2013; 81: 136-147.
11. Bose S, Roy M, Bandyopadhyay A. Recent advances in bone tissue engineering scaffolds. Trends Biotechnol 2012; 30: 546-554.
12. Takasaki W, Kajino Y, Kajino K, Murali R, Greene MI. Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNFα binding to its receptor. Nat Biotechnol 1997; 15: 1266-1270.
13. Aoki K, Alles N, Soysa N, Ohya K. Peptide-based delivery to bone. Adv Drug Deliv Rev 2012; 64: 1220-1238.
14. Dettin M, Bagno A, Morpurgo M, Cacchioli A, Conconi MT, Di Bello C et al. Evaluation of silicon dioxide-based coating enriched with bioactive peptides mapped on human vitronectin and fibronectin: In vitro and in vivo assays. Tissue Eng 2006; 12: 3509-3523.
15. Lee JY, Choi YS, Lee SJ, Chung CP, Park YJ. Bioactive peptide-modified biomaterials for bone regeneration. Curr Pharm Des 2011; 17: 2663-2676.
16. Molek P, Strukelj B, Bratkovic T. Peptide phage display as a tool for drug discovery: Targeting membrane receptors. Molecules 2011; 16: 857-887.
17. Slingluff CL Jr.. The present and future of peptide vaccines for cancer: Single or multiple, long or short, alone or in combination?. Cancer J 2011; 17: 343-350.
18. Whitfield JF, Morley P, Willick GE. Parathyroid hormone, its fragments and their analogs for the treatment of osteoporosis. Treat Endocrinol 2002; 1: 175-190.
19. Subbiah V, Madsen VS, Raymond AK, Benjamin RS, Ludwig JA. Of mice and men: Divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int 2010; 21: 1041-1045.
20. Zhao Q, Wang X, Liu Y, He A, Jia R. NFATc1: Functions in osteoclasts. Int J Biochem Cell Biol 2010; 42: 576-579.
21. Nakashima T, Hayashi M, Takayanagi H. New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol Metab 2012; 23: 582-590.
22. Soysa NS, Alles N, Aoki K, Ohya K. Osteoclast formation and differentiation: An overview. J Med Dent Sci 2012; 59: 65-74.
23. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176.
24. Xiong J, Onal M, Jilka RL,Weinstein RS, Manolagas SC, O'Brien CA. Matrix-embedded cells control osteoclast formation. Nat Med 2011; 17: 1235-1241.
25. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3: 889-901.
26. Takayanagi H. Osteoimmunology: Shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007; 7: 292-304.
27. Nakashima T, Takayanagi H. The dynamic interplay between osteoclasts and the immune system. Arch Biochem Biophys 2008; 473: 166-171.
28. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005; 202: 1261-1269.
29. Aliprantis AO, Ueki Y, Sulyanto R, Park A, Sigrist KS, Sharma SM et al. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest 2008; 118: 3775-3789.
30. Duong LT, Lakkakorpi PT, Nakamura I, Machwate M, Nagy RM, Rodan GA. PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of αvβ3 integrin, and phosphorylated by src kinase. J Clin Invest 1998; 102: 881-892.
31. Boron WF, Boulpaep EL (eds). Medical Physiology. Saunders: New York, NY, USA, 2012.
32. Cherny RC, Honan MA, Thiagarajan P. Site-directed mutagenesis of the arginine-glycineaspartic acid in vitronectin abolishes cell adhesion. J Biol Chem 1993; 268: 9725-9729.
33. Shin TM, Isas JM, Hsieh CL, Kayed R, Glabe CG, Langen R et al. Formation of soluble amyloid oligomers and amyloid fibrils by the multifunctional protein vitronectin. Mol Neurodegener 2008; 3: 16.
34. Hynes RO. Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
35. Mandicourt G, Iden S, Ebnet K, Aurrand-Lions M, Imhof BA. JAM-C regulates tight junctions and integrin-mediated cell adhesion and migration. J Biol Chem 2007; 282: 1830-1837.
36. Owen JD, Ruest PJ, Fry DW, Hanks SK. Induced focal adhesion kinase (FAK) expression in FAK-null cells enhances cell spreading and migration requiring both auto- and activation loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of Pyk2. Mol Cell Biol 1999; 19: 4806-4818.
37. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C et al. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 2007; 282: 14845-14852.
38. Lee JH, Kim CS, Choi KH, Jung UW, Yun JH, Choi SH et al. The induction of bone formation in rat calvarial defects and subcutaneous tissues by recombinant human BMP-2, produced in Escherichia coli. Biomaterials 2010; 31: 3512-3519.
39. Huang H, Chang EJ, Ryu J, Lee ZH, Lee Y, Kim HH. Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway. Biochem Biophys Res Commun 2006; 351: 99-105.
40. Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM et al. NF-κB p50 and p52 regulate receptor activator of NF-κB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem 2007; 282: 18245-18253.
41. Lakkakorpi PT, Bett AJ, Lipfert L, Rodan GA, Duong LT. PYK2 autophosphorylation, but not kinase activity, is necessary for adhesion-induced association with c-Src, osteoclast spreading, and bone resorption. J Biol Chem 2003; 278: 11502-11512.
42. Izawa T, Zou W, Chappel JC, Ashley JW, Feng X, Teitelbaum SL. c-Src links a RANK/αvβ3 integrin complex to the osteoclast cytoskeleton. Mol Cell Biol 2012; 32: 2943-2953.
43. Zou W, Kitaura H, Reeve J, Long F, Tybulewicz VL, Shattil SJ et al. Syk, c-Src, the αvβ3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol 2007; 176: 877-888.
44. Polimeni G, Xiropaidis AV, Wikesjo UM. Biology and principles of periodontal wound healing/regeneration. Periodontol 2000 2006; 41: 30-47.
45. Villar CC, Cochran DL. Regeneration of periodontal tissues: Guided tissue regeneration. Dent Clin North Am 2010; 54: 73-92.
46. Richardson A, Parsons T. A mechanism for regulation of the adhesion-associated protein tyrosine kinase pp125FAK. Nature 1996; 380: 538-540.
47. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src protooncogene leads to osteopetrosis in mice. Cell 1991; 64: 693-702.
48. Yu B, Chang J, Liu Y, Li J, Kevork K, Al-Hezaimi K et al. Wnt4 signaling prevents skeletal aging and inflammation by inhibiting nuclear factor-κB. Nat Med 2014; 20: 1009-1017.
49. Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: An inflammatory tale. J Clin Invest 2006; 116: 1186-1194.
50. Min BM, Lee G, Kim SH, Nam YS, Lee TS, Park WH. Electrospinning of silk fibroin nanofibers and its effect on the adhesion and spreading of normal human keratinocytes and fibroblasts in vitro. Biomaterials 2004; 25: 1289-1297.
51. Yeo IS, Oh JE, Jeong L, Lee TS, Lee SJ, Park WH et al. Collagen-based biomimetic nanofibrous scaffolds: Preparation and characterization of collagen/silk fibroin bicomponent nanofibrous structures. Biomacromolecules 2008; 9: 1106-1116.
52. Toma JG, Akhavan M, Fernandes KJ, Barnabe-Heider F, Sadikot A, Kaplan DR et al. Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol 2001; 3: 778-784.
53. Fernandes KJ, McKenzie IA, Mill P, Smith KM, Akhavan M, Barnabe-Heider F et al. A dermal niche for multipotent adult skin-derived precursor cells. Nat Cell Biol 2004; 6: 1082-1093.
54. Kim JM, Park WH, Min BM. The PPFLMLLKGSTR motif in globular domain 3 of the human laminin-5 α3 chain is crucial for integrin α3β1 binding and cell adhesion. Exp Cell Res 2005; 304: 317-327.
55. McGuffin LJ, Bryson K, Jones DT. The PSIPRED protein structure prediction server. Bioinformatics 2000; 16: 404-405.
56. Lavoie JF, Biernaskie JA, Chen Y, Bagli D, Alman B, Kaplan DR et al. Skin-derived precursors differentiate into skeletogenic cell types and contribute to bone repair. Stem Cells Dev 2009; 18: 893-905.
57. Böttcher RT. β1 integrin cell-surface immunoprecipitation (selective immunoprecipitation). Bioprotocol 2013; 3: E962.
58. Lee JH, Kim HN, Yang D, Jung K, Kim HM, Kim HH et al. Trolox prevents osteoclastogenesis by suppressing RANKL expression and signaling. J Biol Chem 2009; 284: 13725-13734.